Last reviewed · How we verify
Irinotecan+Carboplatin/concurrent radiation
Irinotecan and carboplatin are chemotherapy agents combined with concurrent radiation therapy to damage cancer cell DNA through multiple mechanisms while radiation directly destroys tumor tissue.
Irinotecan and carboplatin are chemotherapy agents combined with concurrent radiation therapy to damage cancer cell DNA through multiple mechanisms while radiation directly destroys tumor tissue. Used for Locally advanced non-small cell lung cancer (NSCLC).
At a glance
| Generic name | Irinotecan+Carboplatin/concurrent radiation |
|---|---|
| Sponsor | West Japan Thoracic Oncology Group |
| Drug class | Chemotherapy combination with concurrent radiation |
| Target | Topoisomerase I (irinotecan); DNA (carboplatin and radiation) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Irinotecan is a topoisomerase I inhibitor that prevents DNA unwinding and repair, while carboplatin is a platinum-based alkylating agent that cross-links DNA strands. When combined with concurrent radiation therapy, these agents work synergistically to induce DNA damage in cancer cells, with radiation providing direct cytotoxic effects. This multimodal approach is designed to improve local and systemic tumor control.
Approved indications
- Locally advanced non-small cell lung cancer (NSCLC)
Common side effects
- Neutropenia
- Anemia
- Thrombocytopenia
- Nausea and vomiting
- Diarrhea
- Esophagitis
- Pneumonitis
- Fatigue
Key clinical trials
- Folfox+Irinotecan+Chemort In Esophageal Cancer (PHASE2)
- Irinotecan, Carboplatin and Radiation Therapy Followed by Bevacizumab in Limited Stage Small Cell Lung Cancer (PHASE2)
- A Phase Ⅲ Randomized Study of Mitomycin/Vindesine/Cisplatin Versus Irinotecan/Carboplatin Versus Paclitaxel/Carboplatin With Concurrent Thoracic Radiotherapy for Unresectable Stage Ⅲ Non-Small-Cell Lung Cancer (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: